Cargando…

Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases

BACKGROUND: The efficacy of anti‐programmed cell death‐1/ligand 1 antibody monotherapy (anti‐PD‐1/PD‐L1 monotherapy) in patients with active brain metastases (BMs) is not established. Here, we aimed to evaluate the efficacy of anti‐PD‐1/PD‐L1 monotherapy in non‐small cell lung cancer (NSCLC) patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tozuka, Takehiro, Kitazono, Satoru, Sakamoto, Hiroaki, Yoshida, Hiroshi, Amino, Yoshiaki, Uematsu, Shinya, Yoshizawa, Takahiro, Hasegawa, Tsukasa, Ariyasu, Ryo, Uchibori, Ken, Yanagitani, Noriko, Horai, Takeshi, Seike, Masahiro, Gemma, Akihiko, Nishio, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471023/ https://www.ncbi.nlm.nih.gov/pubmed/32657011 http://dx.doi.org/10.1111/1759-7714.13557

Ejemplares similares

Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors
por: Tozuka, Takehiro, et al.
Publicado: (2020)

Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2
por: Uchibori, Ken, et al.
Publicado: (2021)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021)

Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
por: Ariyasu, Ryo, et al.
Publicado: (2020)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
por: Ariyasu, Ryo, et al.
Publicado: (2023)

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy
por: Amino, Yoshiaki, et al.
Publicado: (2023)

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients
por: Kitazono, Satoru, et al.
Publicado: (2019)

Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer
por: Low, Siew-Kee, et al.
Publicado: (2022)

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01)
por: Uematsu, Shinya, et al.
Publicado: (2022)

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms
por: Yanagitani, Noriko, et al.
Publicado: (2020)

Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR
por: Ariyasu, Ryo, et al.
Publicado: (2021)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
por: Yoshizawa, Takahiro, et al.
Publicado: (2021)

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer
por: Takahashi, Ken, et al.
Publicado: (2020)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
por: Sonoda, Tomoaki, et al.
Publicado: (2018)

Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of ACTN4 According to Evaluation of Metastatic Ability
por: Tozuka, Takehiro, et al.
Publicado: (2022)

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
por: Kawashima, Yosuke, et al.
Publicado: (2019)

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
por: Tozuka, Takehiro, et al.
Publicado: (2023)

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
por: Shimizu, Yuki, et al.
Publicado: (2022)

Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report
por: Hayashi, Anna, et al.
Publicado: (2022)

Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2020)

Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
por: Tozuka, Takehiro, et al.
Publicado: (2018)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
por: Sugano, Teppei, et al.
Publicado: (2018)

Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
por: Sagawa, Ray, et al.
Publicado: (2022)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis
por: Tozuka, Takehiro, et al.
Publicado: (2018)

Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
por: Misawa, Kazuhito, et al.
Publicado: (2023)

Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer
por: Ogusu, Shinsuke, et al.
Publicado: (2023)

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
por: Terai, Hideki, et al.
Publicado: (2022)

Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study
por: Hisakane, Kakeru, et al.
Publicado: (2023)

Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer
por: Uchida, Hideaki, et al.
Publicado: (2023)

Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
por: Iso, Hirokazu, et al.
Publicado: (2023)

A Japanese boy with fructose-1,6-bisphosphatase deficiency who had a novel FBP1 mutation (p.Phe90Val)
por: Nagahara, Keiko, et al.
Publicado: (2017)

Acute respiratory failure due to Aspergillus niger infection with acute fibrinous and organazing pneumonia: A case report
por: Okamura, Ken, et al.
Publicado: (2022)

Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia
por: Sekiguchi, Naohiro, et al.
Publicado: (2022)

Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer
por: Omori, Miwako, et al.
Publicado: (2022)

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
por: Gong, Bo, et al.
Publicado: (2019)

Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro
por: Moriyama, Gaku, et al.
Publicado: (2018)

Reconstitution and characterization of the unconventional splicing of XBP1u mRNA in vitro
por: Shinya, Sayoko, et al.
Publicado: (2011)

Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI
por: Yamamoto, Ko, et al.
Publicado: (2023)

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)
por: Tanaka, Hisashi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3390cik5g8p17m9cf5n4pc1rne